J. Kusel

The who-choice cost-effectiveness Threshold: a Country-level analysis of changes over time

Mark D. Griffiths, M. Maruszczak, J. Kusel · Value in Health · 2015 · 38 citations

Pharmacy, Economics, Pharmacoeconomics +11

A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK

Stephen Montgomery, M. Maruszczak, David Slater et al. · Journal of Medical Economics · 2016 · 20 citations

Pharmacy, Pharmacoeconomics, Cost-effectiveness Analysis +16

The Impact Of Nice’s End-Of-Life Threshold On Patient Access To New Cancer Therapies In England And Wales

Gavin Stewart, Lucy A. Eddowes, L. Hamerslag et al. · Value in Health · 2014 · 17 citations

Pharmacy, Oncology, Pharmacoeconomics +15

The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis

Le H. Hua, Carrie M. Hersh, Peter Morten et al. · Journal of Managed Care & Specialty Pharmacy · 2019 · 17 citations · Full text

Pharmacy, Economics, Pharmacoeconomics +17

The impact of smoking in the home on the health outcomes of non-smoker occupants in the UK

J. Kusel, Beth Timm, Ian Lockhart · Tobacco Induced Diseases · 2013 · 16 citations · Full text

Public Health, Health Sciences, Preventive Medicine +17